CStone Pharmaceuticals, a Chinese biopharma firm backed by Singapore’s sovereign wealth fund GIC, has raised HK$2.2 billion ($285 million) in its initial public offering (IPO) in Hong Kong after selling 186.4 million shares at HK$12 apiece.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
